Scythian Biosciences Announces Director Resignation
July 26, 2018 (Source) — Scythian Biosciences Corp. (to be renamed Sol Global Investments Corp.) (the “Company” or “Scythian”) (TSXV:SCYB) (Frankfurt:9SB) (OTC – Nasdaq Intl:SCCYF) today announced that Mr. George Scorsis has resigned from its board of directors, and that Rob Reid has been appointed Interim Chairman.
George Scorsis said: “It’s been a great pleasure to help guide Scythian on its journey to becoming the global cannabis player it is today, and I have no doubt the company will continue to make great strides in its research and expansion efforts. I will be leaving with nothing but appreciation and admiration for my colleagues, and a deep respect for all that Scythian has achieved. I look forward to focussing on the rapid growth of Liberty Health Sciences and to guiding it through the swiftly changing regulatory landscape in which Liberty will continue its path to becoming a leader in the U.S. through strategic expansion and an unwavering focus on the patient.”
Rob Reid said: “We thank George for his significant contributions to Scythian. He has always embodied the highest level of integrity while also ensuring that Scythian continued to deliver on the expectations of the shareholders. He has laid the solid foundation we will build upon as we move forward, and we wish him success as he and the Liberty team continue to develop in the U.S. as a dominant player.”
The Company will be announcing further material news and the trading halt will remain in place until after that announcement.
About Scythian Biosciences Corp.
Scythian is an international cannabis company with a focus on the world’s leading markets outside of Canada. Its fast tracked growth has come through a number of strategic investments and regional partnerships in cultivation, distribution and branded products across Europe, United States, South America and the Caribbean. These significant endeavors complement the company’s R&D partnerships with some of the world’s leading universities. It is this comprehensive approach that is positioning Scythian as a future global frontrunner in the medical cannabis industry.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This press release contains certain forward-looking information and statements (“forward-looking information”) within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation, statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions.
Readers are cautioned to not place undue reliance on forward-looking information. Forward-looking information is subject to a number of risks and uncertainties that may cause actual results or events to differ materially from those contemplated in the forward-looking information, and even if such actual results or events are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on the Company.
Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those contained in the forward-looking information, there can be other factors that cause results or events to not be as anticipated, estimated or intended. Risk factors can also be found in the Company’s annual information form filed on SEDAR and available at www.sedar.com.
The forward-looking information contained in this press release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.